170688-63-8

Upstream product

• 197643-97-3 C₁₂H₁₅NO₄ 
• 74279-63-3 2-(4-methoxyphenyl)-2-methylglycine 
• 197643-98-4 (S)-(+)-α-acetamido-4-methoxy-α-methylbenzeneacetic acid 

Downstream Products

• 170689-16-4 (S)-2-Amino-2-(4-methoxy-phenyl)-propionic acid ethyl ester 
• 959691-74-8 (S)-4-[3,4-dimethyl-2,5-dioxo-4-(4-hydroxyphenyl)imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile 
• 959694-11-2 (S)-4-[2,5-dioxo-4-(4-methoxyphenyl)-4-methylimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile 
• 959694-01-0 (S)-4-[3,4-dimethyl-2,5-dioxo-4-(4-methoxyphenyl)imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile 
• 197644-06-7 {4-[(S)-2-[(R)-2-(tert-Butyl-dimethyl-silanyloxy)-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-2-(4-methoxy-phenyl)-propionylamino]-benzyl}-phosphonic acid diethyl ester 

Relevant academic research and scientific papers

Efficient biocatalytic synthesis of highly enantiopure α-alkylated arylglycines and amides

A number of racemic α-alkylarylglycine amides including 1-amino-1-carbamoyl-1,2,3,4-tetrahydronaphthalene underwent efficient biocatalytic hydrolysis under very mild conditions to afford the corresponding (S)-α-alkylarylglycines and (R)-α-alkylarylglycine

Discovery of diarylhydantoins as new selective androgen receptor modulators

A novel selective androgen receptor modulator scaffold has been discovered through structural modifications of hydantoin antiandrogens. Several 4-(4-hydroxyphenyl)-N-arylhydantoins displayed partial agonism with nanomolar in vitro potency in transactivation experiments using androgen receptor (AR) transfected cells. In a standard castrated male rat model, several compounds showed good anabolic activity on levator ani muscle, dissociated from the androgenic activity on ventral prostate, after oral dosing at 30 mg/kg. (+)-4-[3,4-Dimethyl-2,5-dioxo-4-(4-hydroxyphenyl)imidazolidin-1-yl] -2-(trifluoromethyl)benzonitrile ((+)-11b) displayed anabolic potency with a strong dissociation between levator ani muscle and ventral prostate (A 50 = 0.5 mg/kg vs 70 mg/kg). The binding modes of two compounds, including (+)-11b, within the AR ligand-binding domain have been studied by cocrystallization experiments using a coactivator-like peptide. Both compounds bound to the same site, and the overall structures of the AR were very similar.

BMS-201620: A selective beta 3 agonist

A series of N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides were prepared and evaluated for their human β3 adrenergic receptor agonist activity. SAR studies led to the identification of BMS-201620 (39), a potent β3 full agonist (Ki=93nM, 93% activation). Based on its favorable safety profile, BMS-201620 was chosen for clinical evaluation.

Applications of the sulfinimine-mediated asymmetric strecker synthesis to the synthesis of α-alkyl α-amino acids

Addition of Et2AlCN and i-PrOH to ketosulfinimines (N-sulfinyl imines) affords corresponding α-alkyl α-amino nitriles in moderate to good yields. The diastereoselectivity is largely dependent on the E/Z isomer ratio of the ketosulfinimine. Hydrolysis of the diastereomerically pure amino nitriles affords enantiopure α-alkyl α-amino acids in moderate to good yields.

CATECHOLAMINE SURROGATES USEFUL AS BETA 3 AGONISTS

Compounds of the formula STR1 and pharmaceutically acceptable salts thereof. These compounds are beta three adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.